Vancouver, BC., December 13, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) shares the Business Insider report regarding the United States Senate decision to pass the Farm Bill, allowing American farmers to plant and harvest hemp.

The move alters the language of a major drug law that had previously remained unchanged for half a century and loosely defined hemp alongside marijuana as a controlled substance. The new bill exempts hemp from that law and defines it as an agricultural product. That means farmers and researchers of hemp now get some of the same benefits as farmers and researchers of other crops, like the ability to apply for insurance and federal grants.

The bill may also boost interest in a nascent but booming $1 billion industry based on a component of the cannabis plant called CBD, which has been touted for a variety of health and wellness claims. CBD is popping up in more and more products, from coffee and tea to supplements and beer.

Marijuana and hemp come from the same plant species, called Cannabis sativa. Both contain THC and CBD. But each plant is its own unique strain of cannabis.

Until recently, hemp was bred almost entirely for industrial uses like manufacturing. As a result, hemp plants today have very low amounts of THC, the psychoactive chemical responsible for marijuana’s high. Instead, hemp plants are often higher in CBD, or cannabidiol, which is also found in marijuana. CBD is now thought to be responsible for several of cannabis’ therapeutic effects.

For example, marijuana-derived CBD is the active ingredient in Epidiolex, a syrup that is the first cannabis-based drug to gain US government approval for medical use this summer. The drug treats two rare forms of childhood epilepsy.

One thing that is clear from the new bill is that commerce involving hemp is now in the clear. Federally-insured banks, for example, have the green light for the first time to work with industrial hemp producers.

About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that when completed is anticipated to have over 1.8 million square feet of production space. MYM is a shareholder in a project in New South Wales, Australia, an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).